Novartis/Alcon: why the last 23% is worth the extra mile
This article was originally published in Scrip
Executive Summary
Why is Novartis so doggedly pursuing full ownership of Alcon, an M&A transaction that rates among the most protracted the Swiss pharma group has ever undertaken?